SCHEMBL4779714

SCHEMBL4779714

CCOC(=O)C(=Cc1ccc(Cl)s1)C(=O)c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.51
ALDH1A1 P00352 5/20 0.51
KMT2A Q03164 8/20 0.50
MEN1 O00255 7/20 0.50
CNR2 P34972 2/20 0.45
HPGD P15428 2/20 0.43
KDM4E B2RXH2 2/20 0.43
HSP90AA1 P07900 1/20 0.43
LMNA P02545 4/20 0.42
NPSR1 Q6W5P4 4/20 0.42
NFKB1 P19838 2/20 0.42
NFKB2 Q00653 2/20 0.42
RELA Q04206 2/20 0.42
GPR55 Q9Y2T6 1/20 0.42
TDP1 Q9NUW8 2/20 0.41
POLB P06746 2/20 0.41
GAA P10253 2/20 0.41
PLIN1 O60240 1/20 0.41
PLIN5 Q00G26 1/20 0.41
ABHD5 Q8WTS1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4779706 1.00 MAPT (0.51) MAPTALDH1A1KMT2AMEN1CNR2
SCHEMBL4771947 0.83 GLO1 (0.47) MAPTALDH1A1KMT2AMEN1HPGD
SCHEMBL4771944 0.83 GLO1 (0.47) MAPTALDH1A1KMT2AMEN1HPGD
SCHEMBL4775127 0.80 MEN1 (0.42) MAPTALDH1A1KMT2AMEN1HPGD
SCHEMBL4775121 0.80 MEN1 (0.42) MAPTALDH1A1KMT2AMEN1HPGD
SCHEMBL4778528 0.78 KMT2A (0.81) MAPTALDH1A1KMT2AMEN1CNR2
SCHEMBL4778536 0.78 KMT2A (0.81) MAPTALDH1A1KMT2AMEN1CNR2
SCHEMBL11688124 0.78 KMT2A (0.81) MAPTALDH1A1KMT2AMEN1CNR2
SCHEMBL10414069 0.78 KMT2A (0.76) MAPTALDH1A1KMT2AMEN1CNR2
SCHEMBL10414068 0.78 KMT2A (0.76) MAPTALDH1A1KMT2AMEN1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7459451-B2 e.g. 1-Ethyl-4-(5-methyl-3-pyridyl)-6-phenyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid; phosphodiesterase (PDE)-IV inhibitor or tumor necrosis factor (TNF)- alpha antagonist; autoimmune diseases, antidepressant, anxiolytic agent; polychondritis, scleroderma, fibrosis, arthritis, Alzheimer's disease ASTELLAS PHARMA INC. (JP) 2008-12-02 US disclosed
EP-1763528-B1 PYRAZOLOPYRIDINE DERIVATIVES ASTELLAS PHARMA INC (JP) 2008-11-26 EP disclosed
EP-1763528-A1 PYRAZOLOPYRIDINE DERIVATIVES Astellas Pharma Inc. (JP) 2007-03-21 EP disclosed
WO-2006004188-A1 PYRAZOLOPYRIDINE DERIVATIVES ASTELLAS PHARMA INC. (JP) 2006-01-12 WO disclosed
US-20060004003-A1 Pyrazolopyridine derivatives ASTELLAS PHARMA INC. (JP) 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004003-A1 Pyrazolopyridine derivatives PDE4A, PDE3B, PDE5A MAPT 2816/4885ALDH1A1 774/4885KMT2A 3727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.